Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1507822 | 0.94 | PTGS2 (0.49) | SMN1; SMN2PTGS2ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL15426838 | 0.94 | MEN1 (0.53) | SMN1; SMN2PTGS2ALDH1A1CYP2C19MAPT | |
| SCHEMBL1507830 | 0.91 | PTGS2 (0.47) | SMN1; SMN2PTGS2ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL14039419 | 0.91 | ALDH1A1 (0.47) | SMN1; SMN2PTGS2ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL14039512 | 0.91 | PTGS2 (0.47) | SMN1; SMN2PTGS2ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL12227872 | 0.89 | SMN1; SMN2 (0.54) | SMN1; SMN2PTGS2ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL7848337 | 0.89 | SMN1; SMN2 (0.69) | SMN1; SMN2PTGS2ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL12807303 | 0.88 | GAA (0.51) | SMN1; SMN2PTGS2ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL12227868 | 0.87 | SMN1; SMN2 (0.56) | SMN1; SMN2PTGS2ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL12227871 | 0.87 | PPARD (0.52) | PTGS2ALDH1A1PPARDPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305246-B1 | Tumor necrosis factor inhibitors | UNIV PENNSYLVANIA (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-2305246-B1 | Tumor necrosis factor inhibitors | UNIV PENNSYLVANIA (US) | 2015-08-26 | — | — | EP | disclosed |
| US-9096607-B2 | Tumor necrosis factor inhibitors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096607-B2 | Tumor necrosis factor inhibitors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096607-B2 | Tumor necrosis factor inhibitors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140256803-A1 | TUMOR NECROSIS FACTOR INHIBITORS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256803-A1 | TUMOR NECROSIS FACTOR INHIBITORS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256803-A1 | TUMOR NECROSIS FACTOR INHIBITORS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-09-11 | — | — | US | disclosed |
| US-8765810-B2 | Tumor necrosis factor inhibitors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765810-B2 | Tumor necrosis factor inhibitors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2298295-A1 | Tumor necrosis factor inhibitors | Ception Therapeutics, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2298295-A1 | Tumor necrosis factor inhibitors | Ception Therapeutics, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20090221527-A1 | TUMOR NECROSIS FACTOR INHIBITORS | CEPTION THERAPEUTICS, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090221527-A1 | TUMOR NECROSIS FACTOR INHIBITORS | CEPTION THERAPEUTICS, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090221527-A1 | TUMOR NECROSIS FACTOR INHIBITORS | CEPTION THERAPEUTICS, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090155714-A1 | PHOTOSENSITIVE COMPOUND AND PHOTORESIST COMPOSITION INCLUDING THE SAME | DONGJIN SEMICHEM CO., LTD. (KR) | 2009-06-18 | — | — | US | disclosed |
| EP-1845970-A4 | TUMOR NECROSIS FACTOR INHIBITORS | CEPTION THERAPEUTICS INC (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-1845970-A2 | TUMOR NECROSIS FACTOR INHIBITORS | Ception Therapeutics, Inc. (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006083970-A2 | TUMOR NECROSIS FACTOR INHIBITORS | CEPTION THERAPEUTICS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006083869-A2 | TUMOR NECROSIS FACTOR INHIBITORS | CEPTION THERAPEUTICS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221527-A1 | TUMOR NECROSIS FACTOR INHIBITORS | TNFRSF1A, TNF, TNFRSF9 | SMN1; SMN2 4740/4885PTGS2 280/4885ALDH1A1 3912/4885 |
| US-20140256803-A1 | TUMOR NECROSIS FACTOR INHIBITORS | TNFRSF1A, TNF, TNFRSF9 | SMN1; SMN2 4740/4885PTGS2 280/4885ALDH1A1 3912/4885 |
| US-20090155714-A1 | PHOTOSENSITIVE COMPOUND AND PHOTORESIST COMPOSITION INCLUDING THE SAME | CRY1, CRY2, PPOX | SMN1; SMN2 4847/4885PTGS2 460/4885ALDH1A1 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.